Novartis reports new Phase III data showing omalizumab significantly improves itch in patients with severe form of chronic skin disease CSU[1]
26 June 2013 | By Novartis
Novartis announced late-breaking results...
List view / Grid view
News
Rigaku Raman delivers new software enhancements to its Xantus-2 portable analyzer
25 June 2013 | By Rigaku
Rigaku Raman Technologies has announced software enhancements to its leading Xantus-2™ dual-wavelength portable Raman analyzer...
Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at ADA
25 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with an increased risk of cardiovascular events in the treatment of Type 2 Diabetes (T2D), versus a number of…
GSK announces data from five Phase III studies of albiglutide
24 June 2013 | By GlaxoSmithKline
Data from five long-term Phase III studies comparing albiglutide...
Global study finds one in five feel discriminated against because of their diabetes
24 June 2013 | By Novo Nordisk
Key results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™)...
Sandoz launches Phase III clinical trial for biosimilar etanercept
24 June 2013 | By Novartis
Sandoz has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen's Enbrel®)...
Application submitted to the EMA for use of Pradaxa® in treatment of DVT and PE and prevention of recurrent DVT and PE
24 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the submission of an application to the EMA...
New retrospective analysis supports clinical data – Victoza® provides improved blood sugar control compared to sitagliptin and exenatide
22 June 2013 | By Novo Nordisk
Findings from a new real-world study...
Sanofi announces positive Phase 3 results for investigational new insulin U300
22 June 2013 | By Sanofi
Topline results of EDITION II consistent with EDITION I findings...
Dolomite expertise brings microfluidic product to market
21 June 2013 | By kdm communications limited
Fledgling spin-out company Drop-Tech has turned to microfluidics specialist Dolomite for its product development and fabrication skills...
FDA grants breakthrough therapy designation to Novartis’ serelaxin (RLX030) for acute heart failure
21 June 2013 | By Novartis
RLX030 has the potential to address a serious unmet medical need...
Lundbeck plans re-structure to improve its ability to launch new medicines
20 June 2013 | By H. Lundbeck A/S
Lundbeck's initiative could lead to a reduction of around 50-55 positions in Europe...
Pfizer, GSK, and Siemens form R&D Consortium with ICES
20 June 2013 | By A*STAR Institute of Chemical and Engineering Sciences (ICES)
New programme aims to increase productivity with technology solutions for pharmaceutical and chemical sectors...
New test to help doctors determine personalized treatment path for patients with hepatitis C
20 June 2013 | By Abbott
Abbott has introduced the first FDA-approved HCV genotyping test...
FDA approves U.S. product labeling update for Sprycel®
20 June 2013 | By Bristol-Myers Squibb Company
Data added to Sprycel U.S. labeling are among the longest follow-up data of current CML treatment options...
